Hemarina
The Hemarina technological platform is based on the peculiarities of the purified hemoglobin of lugworms, Arenicola marina . Its structure is comparable to that of human hemoglobin, however it is distinguished by: its extracellular character (it is not contained in a red blood cell), and therefore universal (compatibility with all blood groups) its ability to bind 40 times more oxygen than human hemoglobin its particularly small size: 250 times smaller than the human red blood cell
2
Funding Rounds
$4.8m
Money raised
Overview
The Hemarina technological platform is based on the peculiarities of the purified hemoglobin of lugworms, Arenicola marina . Its structure is comparable to that of human hemoglobin, however it is distinguished by: its extracellular character (it is not contained in a red blood cell), and therefore universal (compatibility with all blood groups) its ability to bind 40 times more oxygen than human hemoglobin its particularly small size: 250 times smaller than the human red blood cell
Funding
Funding series
Funding Series Analysis
The company Hemarina has raised a total of $4.79m in funding over 2 rounds.
Key Insights:
- Hemarina Series B round: $3.7m
- Hemarina Series A round: $1.09m
Hemarina Series B round
$3.7m
Hemarina Series A round
$1.09m
Industries
Hemarina is active in the following industries: